Telix Pharmaceuticals Limited announced that the Board of Directors has granted Dr. Andreas Kluge, on his request, a leave of absence, for a period of approximately six months, from his current role as a Non-Executive Director of Telix, to enable him to deal with personal issues. The Telix Board anticipates that Dr. Kluge will return from his leave of absence on or around 29 September 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.59 AUD | -1.20% | +3.45% | +54.66% |
05-21 | Telix Pharmaceuticals Concludes Proof-of-Concept Study of Advanced Prostate Cancer Drug | MT |
05-20 | Telix Pharmaceuticals Files Registration Statement for Nasdaq IPO | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.66% | 3.5B | |
+64.52% | 62.59B | |
-1.31% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.49% | 26.21B | |
-21.66% | 19.09B | |
+4.85% | 13.08B | |
+25.57% | 12.26B | |
+28.14% | 12.05B |
- Stock Market
- Equities
- TLX Stock
- News Telix Pharmaceuticals Limited
- Telix Pharmaceuticals Limited Grants Andreas Kluge a Leave of Absence from his Role as Non-Executive Director